The Computational Modelling and Epidemiology section aims to allow rapid communication of methods and results that utilize computational modeling and epidemiologic approaches in translational medicine. The focus will be on population-based studies that extend towards more molecular level analysis.
Edited by Michael Liebman and Sabrina Molinaro, submission of studies involving methods development is encouraged where actual application and results can be shown in the healthcare and life sciences domains.
Read the latest articles in the Computational Modelling and Epidemiology section
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex and debilitating disease accompanied by muscular fatigue and pain. A functional measure to assess muscle fatigability of ME/CFS patients is, however, not established in clinical routine.
In this study, Jäkel and colleagues aimed to evalulate muscle fatigability as a diagnostic tool and its correlation with clinical parameters by assessing repeat maximum handgrip strength (HGS). Findings revealed that patients with ME/CFS have reduced Fmax and Fmean HGS compared to healthy controls. Repeat HGS assessment is a sensitive diagnostic test to assess muscular fatigue and fatigability and an objective measure to assess disease severity in ME/CFS.
Wirth & Scheibenbogen, 2021
Chronic Fatigue Syndrome or Myalgic Encephaloymelitis (ME/CFS) is a frequent debilitating disease with an enigmatic etiology. The researchers' hypothesis published previously considers ME/CFS as a disease caused by a dysfunctional autonomic nervous system: sympathetic overactivity in the presence of vascular dysregulation by ß2AdR dysfunction causes predominance of vasoconstrictor influences in brain and skeletal muscles, which in the latter is opposed by the metabolically stimulated release of endogenous vasodilators (functional sympatholysis).
In this article, Wirth & Scheibenbogen explain the mechanisms underlying the energetic disturbance in muscles and merge with the first hypothesis. According to the hypothesis dysfunctions of the ß2AdR or post-receptor mechanisms, of the NHE1, the Na+/K+ATPase, the NCX, the RAAS and the KKS could be causally involved in ME/CFS and should therefore be further investigated.
Journal of Translational Medicine has launched In Review, a new option that provides authors with on-demand information on the status of their manuscript, enables them to share their work with funders and their research community, and allows their colleagues to comment and collaborate - all whilst their manuscript is under review.
Read MoreGet to know the Editors behind Journal of Translational Medicine!
Check out last month's top 20 most discussed articles from Journal of Translational Medicine!
nadia_buravleva / stock.adobe.com
Journal of Translational Medicine would like to warmly thank the top reviewers whose comments helped to shape the journal, for their assistance with review of manuscripts in Volume 18 (2020).
Translational Medicine Communications. the companion journal to Journal of Translational Medicine, is an interdisciplinary forum for all scientifically valid research from across translational medicine.
The journal aims to improve transparency and reproducibility within translational medicine and considers research papers regardless of outcome or significance of findings.
Led by Section Editor Claire Vanpouille-Box, this new section is interested in innovative research that investigate the crosstalk between ionizing radiations (IR), the tumor microenvironment (TME) and host immunity.
Studies considered for publication include (but not limited to) those investigating the mechanisms of radiation-induced anti-tumor immune responses, the immune-stimulatory and immuno-suppressive properties of ionizing radiation from all sources, biomarkers predictive of immune response, immune escape mechanisms elicited by IR and radioresistance. Importantly, the section welcomes translational and clinical studies assessing the combination of IR with immunotherapies (IT) with an emphasis on clinical response and outcome.
Led by Section Editor Gennaro Ciliberto, this exciting section is dedicated to the wave of emerging therapeutics arising from the intense research efforts and therapeutic breakthroughs based on recent scientific and technological developments.
Emerging Therapeutics is interested in original papers, reviews and perspectives on the advancements in the field, including genetic vaccines, monoclonal antibodies, CAR-Ts, gene therapy with viral vectors, clinical applications of CRISPR/CAS9 gene editing, microbiota-modulating approaches, ‘omics approaches, emerging therapeutics from the development of new technologies for drug development, and discovery of new intervention targets and the possibility for new drug combinations.
Led by Section Editor Souhaila Al Khodor, this new section aims to fill the gap between basic research, translational medicine, and high-throughput data analysis for the human microbiome by providing innovative and novel scientific ideas.
Translational Metagenomics encompasses studies about the development and application of metagenomics, metatranscriptomics, microbial metabolomics or novel bioinformatics tools used to improve our knowledge on the microbiome. The section is especially interested in studies that go beyond description of the microbial composition and include experimental models used to support the proposed role of the microbiome in human health and diseases.
Dr. Marincola received his MD, summa cum laude from the University of Milan, Italy and Surgery training at Stanford University, California. His research interest lies in translational medicine and focuses on the development of strategies for the dynamic study of patients’ response to immunotherapy. His approach has brought seminal observations regarding the mechanisms leading to rejection of tumors, allograft rejection, graft-versus-host disease and autoimmunity.
Dr. Marincola is currently Global Head of Research at Kite Pharma, Santa Monica, California. He previously was President and Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California, Distinguished Research Fellow at AbbVie Corporation in Redwood City, California, Chief Research Officer at Sidra Medical and Research Center in Doha Qatar and Tenured Investigator at the National Institutes of Health, Bethesda Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine of which he is currently the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and of the International Society for Translational Medicine. Dr. Marincola is editor of several biomedical books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is an award winning fiction writer author of The Wise Men of Pizzo and the Cat Behind the Window.
Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.
The journal covers all areas of translational medicine but also has several special sections:
Speed
60 days to first decision for reviewed manuscripts only
34 days to first decision for all manuscripts
115 days from submission to acceptance
13 days from acceptance to publication
Citation Impact
4.124 - 2-year Impact Factor
4.541 - 5-year Impact Factor
1.142 - Source Normalized Impact per Paper (SNIP)
1.474 - SCImago Journal Rank (SJR)
Usage
2,701,735 Downloads
3,471 mentions